Skip to main content

Table 4 OS prognostic score in the FAS and the FAS CORRECT populations

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

FAS Population n = 654

 

Median OS

6-month OS rate

 Score equal to 0,1, 2, or 3 (high benefit from REG, n = 213)

1

9.2

67 %

 Score equal to 4 or 5 (moderate benefit from REG, n = 256)

1.78 (1.45–2.18)

5.2

45 %

 Score equal to 6+ (low benefit from REG, n = 147)

2.70 (2.13–3.42)

2.5

26 %

FAS-CORRECT Population n =440

 Score equal to 0 or 1 (high benefit from REG, n = 185)

1

8.7

64 %

 Score equal to 2 (moderate benefit from REG, n = 206)

1.67 (1.34–2.09)

5.5

46 %

 Score equal to 3 (low benefit from REG, n = 48)

2.54 (1.79–3.60)

3.4

35 %

  1. Relative weights of the variables found independently related to survival (see Table 3) were added to obtain a total score. This score ranged from 0 to 10, and was then reduced to obtain three categories of patients with significantly different risks of death